Clinical trial
A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an…
NCT00055510 · Chugai Pharma USA, Industry · Completed
Key facts
| NCT number | NCT00055510 |
|---|---|
| Title | A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels. |
| Lead sponsor | Chugai Pharma USA, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis |
| Intervention type | Drug |
| Interventions | BO-653 |
| First posted | Mar 5, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: